Related Experiment Video
Updated: Sep 12, 2025
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
Predictors of toxicities and oncological outcomes following postoperative ablative radiotherapy (POPART) for
Federica Ferrario1, Ciro Franzese2, Suela Vukcaj3
1Department of Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Background:
Salvage radiotherapy to the prostate bed (PB) is the standard treatment for biochemical recurrence after radical prostatectomy. Emerging evidence supports hypofractionation, including Stereotactic Body Radiation Therapy (SBRT), in this setting. Predictive factors for toxicity, patient-reported outcomes (PROs) and biochemical recurrence following salvage SBRT to the PB are analyzed in this study.
Materials And Methods:
Patients with histologically confirmed prostate cancer, PSA 0.1-2.0 ng/mL, and no metastases on PSMA PET, received postoperative SBRT to the prostate bed (32.5 Gy in five fractions, every other day). Toxicity was assessed using CTCAE v5.0, while QoL was measured via ICIQ-SF, IIEF 5, and EPIC-CP questionnaires at baseline and follow-up, with MCID defined as changes > 0.5 SD. PSA levels were also measured to assess oncological outcomes. Statistical analyses included ANOVA, logistic and Cox regression models (p < 0.05 significant). Kaplan-Meier analysis estimated biochemical recurrence-free survival (BRFS).
Results:
Between April 2021 and September 2023, 100 patients (median age: 71) were treated with a median follow-up of 19.6 months (range: 3.5-42.4). Acute toxicity analysis showed no ≥ G2 GU events and 5 % G2 GI toxicity. Late toxicity included 6.4 % G2 GU events, 1.1 % G3 radiation cystitis, and 1.1 % G2 GI toxicity. Larger CTV and higher baseline bowel scores were predictors of acute G2 GI toxicity, while acute urinary incontinence MCID predicted late G2 GU toxicity. Higher bladder wall and penile bulb doses were associated with worse urinary and sexual outcomes. Biochemical recurrence occurred in 18 patients, with a median time of 10 months. ISUP grade was a significant predictor of recurrence, with lower BRFS rates in higher-grade tumors.
Conclusions:
SBRT to the PB is a feasible and well-tolerated approach with adequate biochemical control outcomes. Acute symptoms anticipated late side effects. Long-term follow-up and comparative trials are needed to strengthen the role of SBRT in this setting.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...